BioPharma Credit PLC Result of General Meeting (0859Y)

TIDMBPCR

RNS Number : 0859Y

BioPharma Credit PLC

28 December 2023

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF GENERAL MEETING

The Company is pleased to announce that, at the General Meeting held today, the resolution put to the meeting was passed by way of a poll.

 
                                   Votes       %                      %   Votes Withheld(1) 
 Resolution                          For           Votes Against 
 To approve the 
  continuation of 
  the Company's 
  business as a 
  closed-ended investment 
  trust.                     704,196,309   94.06      44,493,800   5.94              21,716 
                            ------------  ------  --------------  -----  ------------------ 
 

1. A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

A copy of the resolution has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

28 December 2023

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

T. [phone]

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

[phone]

[e-mail]

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMFVLFLXLLBFBX

(END) Dow Jones Newswires

December 28, 2023 06:04 ET (11:04 GMT)